We are excited to announce a groundbreaking partnership with The Mark Foundation for Cancer Research (MFCR). Together, we are launching a global initiative to fund innovative research projects exploring the complex connection between aging and cancer.
Later this month we will be inviting leading scientists from across the globe to submit novel research proposals that are focused in this field.
Selected projects will receive $500,000 in funding over three years, during which time, SWCRF along with MFCR, plan to invest up to $11 million into specific aging-cancer research.
This significant financial commitment underscores our organization’s shared dedication to advancing pioneering science and tackling cancer’s toughest challenges.
Since, aging is the leading cause of cancer development and progression, as well as poses many treatment challenges, this area of research is crucial to combating the global rise in cancer incidence and improving outcomes for all cancer patients.
These research projects will address critical topics such as:
- Identifying actionable biomarkers that predict aging/cancer risk.
- Understanding how aging impacts tumor growth.
- Exploring the role of the aging immune system in cancer treatment.
- Investigating how metabolism and genetics contribute to cancer development.
- Studying how premature aging increases cancer risk for younger adults.
By supporting this program, SWCRF is further cementing its international leadership in addressing one of the most urgent challenges in cancer prevention and treatment today.
Your continuing support makes this possible. Please consider donating today to help fund this and other vital research programs.
Let’s work together to end cancer in our lifetime.
Warm regards,
Samuel Waxman, MD
Founder and CEO
William T. Sullivan
Executive Director
CLINICAL BREAKTHROUGHS
New Treatment for Liver Cancer Slows Progression and
Improves Survival
A recent study by SWCRF-investigator, Dr. Josep Llovet (Icahn School of Medicine at Mount Sinai), and colleagues has discovered a new treatment approach for unresectable,
non-metastatic hepatocellular carcinoma (HCC)—a form of liver cancer that cannot be surgically removed and has not yet spread to other parts of the body. Around 45,000 cases of HCC are diagnosed yearly in the US and about 1M globally.
According to their research, published in The Lancet (January 2025), combining transarterial chemoembolisation (TACE) with the drugs lenvatinib (a targeted therapy) and pembrolizumab (an immunotherapy) significantly improved patient outcomes compared to the placebo group.
Specifically, patients receiving this combination therapy experienced slower tumor progression and a trend towards overall higher survival rates. Additionally, the drug combination was well-tolerated, with manageable side effects, supporting its potential as a viable treatment option in patients with intermediate HCC.
“SWCRF has been instrumental in supporting the development of the HCC program at Mount Sinai since 2004. Their commitment to funding innovative cancer research has allowed us to make these significant strides in understanding and treating this devastating disease. This breakthrough would not have been possible without their continued support”, said Dr Josep M Llovet, Professor of Medicine and Director of the Liver Cancer Program at the Ichan School of Medicine.
This remarkable improvement marks the first clinical breakthrough in treating this challenging and often fatal form of cancer in more than 20 years.
|
|
SAVE-THE-DATE
|
|
We’re thrilled to announce an exclusive partnership with Seabourn Cruises.
When you book any Seabourn cruise (excluding World Cruise or Grand Cruise), 10% of your fare will be donated directly to the Samuel Waxman Cancer Research Foundation.
This is your chance to indulge in a luxury cruise experience, while supporting cancer research in a meaningful way.
Select from an array of breathtaking itineraries on eligible voyages through December 25, 2025. Choose from voyages to the Amazon, Arctic, Australia & New Zealand, Asia, the Caribbean, the Mediterranean, and more.
To reserve your next adventure, contact our dedicated Seabourn consultant:
Roseanne Bishop, Personal Cruise Consultant
800.929.4747 Ext. 29398
**Offer Code: WAXMANCRI**
Prefer to book online or through your travel agent? Simply provide the same offer codes.
Join us in this extraordinary journey – a chance to explore the world and make a positive impact in the fight against cancer. Book today!
Samuel Waxman Cancer Research Foundation | Website | Telephone 212-867-4502
